You are here

Article Text

Article menu
Download PDFPDF
Letter
Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo
  1. B Vander Cruyssen,
  2. F De Keyser,
  3. E Kruithof,
  4. H Mielants,
  5. F Van den Bosch
  1. Department of Rheumatology, Ghent University Hospital, Gent, Belgium
  1. Correspondence to:
    B Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, B-9000 Gent, Belgium; bert.vandercruyssen{at}ugent.be

https://doi.org/10.1136/ard.2006.055541

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Psoriatic arthritis (PsA) shares features with the spondyloarthropathy (SpA) concept and with rheumatoid arthritis. Treatment of PsA should target the skin, the SpA-like features and the rheumatoid arthritis-like features of the disease. Effects of treatment can be measured by one index covering different axes at once or by evaluating each axis separately.1 In this analysis, we evaluated different composite indices that have been validated in rheumatoid arthritis and compared them with the Psoriatic Arthritis Response Criteria (PsARC).2

    The study population consisted of 18 patients with PsA, previously enrolled in a randomised monocentre double-blind placebo-controlled study evaluating effect of infliximab in patients with SpA,3 of whom nine received placebo. Patients were evaluated at baseline and at weeks 1, 2, 6, 8 and 12, which included the evaluation of the single components included in the PsARC, the Disease Activity Score using 28 joint counts (DAS28)4 and the DAS response (http://www.das-score.nl). A …

    View Full Text

    Footnotes

    • Competing interests: None declared.